US drug titan Pfizer Monday said it wants to acquire AstraZeneca in a deal potentially worth $100 billion to fortify its pipeline of new medicines and sharply cut its tax bill.
A sign for US drugs giant Pfizer pictured outside the company's headquarters in New York City on January 26, 2009
Pfizer Monday disclosed that it proposed in January a preliminary, non-binding takeover of about $99 billion to AstraZeneca, only to be rejected by the British company. A second effort to revive talks was rebuffed on April 26.
This article is older than 60 days, which we reserve for our premium members only.You can subscribe to our premium member subscription, here.